A. Ari Hakimi
A5089094298- Renal cell carcinoma treatment
- Renal and related cancers
- Cancer Genomics and Diagnostics
- Bladder and Urothelial Cancer Treatments
- Ferroptosis and cancer prognosis
- Cancer Immunotherapy and Biomarkers
- Multiple and Secondary Primary Cancers
- Epigenetics and DNA Methylation
- Urinary and Genital Oncology Studies
- Cancer, Hypoxia, and Metabolism
- Prostate Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Radiomics and Machine Learning in Medical Imaging
- Pediatric Urology and Nephrology Studies
- Renal and Vascular Pathologies
- Cancer, Lipids, and Metabolism
- Immune cells in cancer
- Cancer Diagnosis and Treatment
- Urologic and reproductive health conditions
- Genetic and Kidney Cyst Diseases
- Metabolomics and Mass Spectrometry Studies
- CNS Lymphoma Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Lung Cancer Treatments and Mutations
- Immune Cell Function and Interaction
Memorial Sloan Kettering Cancer Center
2016-2025
Ministry Of Health
2025
Kettering University
2015-2023
Pacific Northwest National Laboratory
2022
Hefei Institutes of Physical Science
2022
Chinese Academy of Sciences
2022
Cornell University
2013-2020
New York Proton Center
2012-2019
Kettering Medical Center
2019
Massachusetts General Hospital
2018
Papillary renal-cell carcinoma, which accounts for 15 to 20% of carcinomas, is a heterogeneous disease that consists various types renal cancer, including tumors with indolent, multifocal presentation and solitary an aggressive, highly lethal phenotype. Little known about the genetic basis sporadic papillary no effective forms therapy advanced exist.We performed comprehensive molecular characterization 161 primary using whole-exome sequencing, copy-number analysis, messenger RNA microRNA...
Tumor-infiltrating immune cells have been linked to prognosis and response immunotherapy; however, the levels of distinct cell subsets signals that draw them into a tumor, such as expression antigen presenting machinery genes, remain poorly characterized. Here, we employ gene expression-based computational method profile infiltration 24 populations in 19 cancer types. We compare types using an score T find clear renal carcinoma (ccRCC) is among highest for both scores. Using profiles well...
Recent clinical trials have demonstrated a clear survival advantage in advanced head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint blockade. These emerging results reveal that HNSCC is one of the most promising frontiers for immunotherapy research. However, further progress immuno-oncology will require detailed understanding infiltrative landscape found these tumors. We leveraged transcriptome data from 280 tumors profiled by The Cancer Genome Atlas (TCGA)...
Renal cell carcinoma (RCC) is not a single disease, but several histologically defined cancers with different genetic drivers, clinical courses, and therapeutic responses. The current study evaluated 843 RCC from the three major histologic subtypes, including 488 clear RCC, 274 papillary 81 chromophobe RCC. Comprehensive genomic phenotypic analysis of subtypes reveals distinctive features each subtype that provide foundation for development subtype-specific management strategies patients...
To elucidate the deregulated functional modules that drive clear cell renal carcinoma (ccRCC), we performed comprehensive genomic, epigenomic, transcriptomic, proteomic, and phosphoproteomic characterization of treatment-naive ccRCC paired normal adjacent tissue samples. Genomic analyses identified a distinct molecular subgroup associated with genomic instability. Integration proteogenomic measurements uniquely protein dysregulation cellular mechanisms impacted by alterations, including...
Mutations, deletions, and changes in copy number of mitochondrial DNA (mtDNA), are observed throughout cancers. Here, we survey mtDNA variation across 22 tumor types profiled by The Cancer Genome Atlas project. We observe a tendency for some cancers, especially the bladder, breast, kidney, to be depleted mtDNA, relative matched normal tissue. Analysis genetic context reveals an association between incidence several somatic alterations, including IDH1 mutations gliomas, content. In but not...
On the basis of multidimensional and comprehensive molecular characterization (including DNA methalylation copy number, RNA, protein expression), we classified 894 renal cell carcinomas (RCCs) various histologic types into nine major genomic subtypes. Site origin within nephron was one determinant in classification, reflecting differences among clear cell, chromophobe, papillary RCC. Widespread changes associated with TFE3 gene fusion or chromatin modifier genes were present a specific...
To investigate the impact of newly identified chromosome 3p21 epigenetic tumor suppressors PBRM1, SETD2, and BAP1 on cancer-specific survival (CSS) 609 patients with clear cell renal carcinoma (ccRCC) from 2 distinct cohorts.Select sequencing 3p 188 who underwent resection primary ccRCC at Memorial Sloan-Kettering Cancer Center (MSKCC) was conducted to interrogate genotype-phenotype associations. These findings were compared analyses genomic clinical dataset our nonoverlapping The Genome...
Treatment with immune checkpoint inhibitors (ICI) has demonstrated clinical benefit for a wide range of cancer types. Because only subset patients experience benefit, there is strong need biomarkers that are easily accessible across diverse practice settings. Here, in retrospective cohort study 1714 16 different types treated ICI, we show higher neutrophil-to-lymphocyte ratio (NLR) significantly associated poorer overall and progression-free survival, lower rates response after ICI therapy...
// Luc G.T. Morris 1,2,* , Nadeem Riaz 1,3* Alexis Desrichard 1 Yasin Şenbabaoğlu 4 A. Ari Hakimi 2 Vladimir Makarov Jorge S. Reis-Filho 1,5 and Timothy Chan 1,3 Human Oncology Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA Department of Surgery, 3 Radiation Oncology, Computational Biology 5 Pathology, * These authors have contributed equally to this work Correspondence to: Morris, email: Chan, Keywords : heterogeneity, evolution, survival, cancer, immune...
Kidney cancer [or renal cell carcinoma (RCC)] is known as "the internist's tumor" because it has protean systemic manifestations, suggesting that utilizes complex, nonphysiologic metabolic pathways. Given the increasing incidence of this and its lack effective therapeutic targets, we undertook an extensive analysis human RCC tissue employing combined grade-dependent proteomics metabolomics to determine how reprogramming occurring in disease allows escape available approaches. After...
Obesity increases risk for clear-cell renal cell carcinoma (ccRCC), yet obese patients appear to experience longer survival than nonobese patients. We examined body mass index (BMI) in relation stage, grade, and cancer-specific mortality (CSM) while considering detection bias, nutritional status, molecular tumor features. Data were available from 2119 ccRCC who underwent surgery at Memorial Sloan-Kettering Cancer Center between 1995 2012. Logistic regression models produced associations BMI...
Purpose To investigate associations between computed tomographic (CT) features of clear cell renal carcinoma (RCC) and mutations in VHL, PBRM1, SETD2, KDM5C, or BAP1 genes. Materials Methods The institutional review board approved this retrospective, hypothesis-generating study 233 patients with RCC waived the informed consent requirement. was HIPAA compliant. Three radiologists independently reviewed pretreatment CT images all RCCs without knowledge their genomic profile. One radiologist...
Abstract Purpose: Rapalogs are allosteric mTOR inhibitors and approved agents for advanced kidney cancer. Reports of clonal heterogeneity in this disease challenge the concept targeted monotherapy, yet a small subset patients derives extended benefit. Our aim was to analyze such outliers explore genomic background extreme rapalog sensitivity context intratumor heterogeneity. Experimental Design: We analyzed archived tumor tissue 5 with renal cell carcinoma, who previously achieved durable...